1. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity

   • Jie Feng
   • Yanqing Wu

   Review Article 26 February 2023 Pages: 231 - 246

   

2. Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease

   • Albert A. Volkl
   • Kenneth Todd Moore
   • Elliot S. Barnathan

   Review Article Open access 28 April 2023 Pages: 247 - 255

3. Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis

   • Nan Zheng
   • Jinyan Zhong
   • Longfu Jiang

   Systematic Review 03 March 2023 Pages: 257 - 267

   

4. Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Systematic Review and Meta-analysis of Anticoagulation Strategy

   • Federico Oliveri
   • Antonella Pepe
   • Stefano Ghio

   Systematic Review 15 April 2023 Pages: 269 - 276

   

5. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects

   • Mason W. Freeman
   • Mary Bond
   • Jonathan Isaacsohn

   Original Research Article Open access 15 February 2023 Pages: 277 - 286

   

6. A Real-World Exploration into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches

   • Ezekwesiri Michael Nwanosike
   • Wendy Sunter
   • Syed Shahzad Hasan

   Original Research Article 06 March 2023 Pages: 287 - 299

   

7. Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021

   • Jun Hao
   • Chen Li
   • Wen Hui

   Original Research Article 14 March 2023 Pages: 301 - 310

   

8. Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease

   • Salil V. Deo
   • David McAllister
   • Jill P. Pell

   Original Research Article 22 March 2023 Pages: 311 - 321

   

9. Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis

   • Hilmi Alnsasra
   • Gal Tsaban
   • Ronen Arbel

   Original Research Article 17 April 2023 Pages: 323 - 328

   

10. Clinical and Hemodynamic Responses to Imatinib in Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis: A Retrospective Pilot Study of Five Cases and Review of the Literature

    • Junichi Nakamura
    • Ichizo Tsujino
    • Satoshi Konno

    Original Research Article 30 March 2023 Pages: 329 - 338